Global research hot points on cardiovascular disease--bibliometric analysis based on the ESI hot papers_Journal of Biomedical Engineering

Authors：

XI Ziqing ¹ , GONG Xiaoqing ² , LI Baihong ³ ,  ZHANG Longhao ³ ,  PU Jian ³ , LI Yin ³ , XU Yuanning ⁴ , ZHANG Mingming ⁵

1. Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
2. Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
3. Double First-class Construction Office, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
4. Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
5. Chinese Evidence Based Med Ctr, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;

Corresponding author：

ZHANG Longhao, Email: zhanglonghao1990@hotmail.com; PU Jian, Email: hxpujian@163.com

Keywords：

cardiovascular disease; research hotspot; bibliometric analysis

DOI：

10.7507/1001-5515.202008001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

With the heavier burden of cardiovascular disease, an abundance of papers emerge every year in the research hotspots, which cover a wide range of types and content. In order to let readers interested in the cardiovascular field quickly understand the research hotspots and research frontier, it is necessary to sort out and summarize the research topic in time. According to the discipline classification, we screened papers in cardiovascular field from the Essential Science Indicators (ESI) hot papers published in 2019. Methods such as bibliometrics, statistical description, hierarchical induction, analysis and interpretation were used a step further to reveal the context and characteristics of research in the field of cardiovascular diseases, summarize the latest progress and development direction in this field, and provide information and hints for the expansion of future research directions. A total of 297 papers were finally included, which were mainly in the field of clinical medicine; The country with the most publications was the United States, while China ranked the fifth in terms of contribution; the research institution with the highest number of published papers was Harvard University; the New England Journal of Medicine (NEJM) has published the most papers, with contribution also from journals such as Circulation, Europe Heart Journal, JAMA, and Lancet. All the papers were categorized into disease burden, disease risk, drug treatment, device treatment and surgical treatment, clinical diagnosis, basic research and others, so as to review and summarize the research front in the field of cardiovascular diseases.

Citation： XI Ziqing, GONG Xiaoqing, LI Baihong, ZHANG Longhao, PU Jian, LI Yin, XU Yuanning, ZHANG Mingming. Global research hot points on cardiovascular disease--bibliometric analysis based on the ESI hot papers. Journal of Biomedical Engineering, 2020, 37(5): 741-748. doi: 10.7507/1001-5515.202008001 Copy

1.	胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要. 中国循环杂志, 2019, 34(3): 209-220.
2.	科睿唯安. InCites - Cardiac&cardiovascular systems [EB/OL]. [2020/7/30]. http://incites.clarivate.com/#/explore/0/subject.
3.	GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar M H, Reitsma M B, et al. Health effects of overweight and obesity in 195 countries over 25 years. New Engl J Med, 2017, 377(1): 13-27.
4.	Lavie C J, Arena R, Alpert M A, et al. Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol, 2018, 15(1): 45-56.
5.	Bohula E A, Wiviott S D, McGuire D K, et al. Cardiovascular safety of lorcaserin in overweigh or obese patients. New Engl J Med, 2018, 379(12): 1107-1117.
6.	Aidin R, Araz R, Stefan F, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. New Engl J Med, 2017, 376(15): 1407-1418.
7.	Holman R R, Bethel M A, Mentz R J, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New Engl J Med, 2017, 377(13): 1228-1239.
8.	Neal B, Perkovic V, Mahaffey K W, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med, 2017, 377(7): 644-657.
9.	Khera A V, Emdin C A, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and risk of coronary artery disease. New Engl J Med, 2016, 375(24): 2349-2358.
10.	NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet, 2017, 389(10064): 37-55.
11.	Sabatine M S, Giugliano R P, Keech A C, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med, 2017, 376(18): 1713-1722.
12.	Nicholls S J, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients the GLAGOV randomized clinical trial. J Am Med Assoc, 2016, 316(22): 2373-2384.
13.	Bonaca M P, Nault P, Giugliano R P, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation, 2018, 137(4): 338-350.
14.	Ridker P M, Everett B M, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New Engl J Med, 2017, 377(12): 1119-1131.
15.	Ridker P M, MacFadyen J G, Thuren T, et al. Effect of interleukin-1 beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 2017, 390(10105): 1833-1842.
16.	Ridker P M, MacFadyen J G, Everett B M, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, 2018, 391(10118): 319-328.
17.	Eikelboom J W, Connolly S J, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. New Engl J Med, 2017, 377(14): 1319-1330.
18.	Weitz J I, Lensing A W A, Prins M H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New Engl J Med, 2017, 5(5): 1211-1222.
19.	Anand S S, Bosch J, Eikelboom J W, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, 2018, 391(10117): 219-229.
20.	Reardon M J, Van Mieghem N M, Popma J J, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. New Engl J Med, 2017, 376(14): 1321-1331.
21.	Mack M J, Leon M B, Thourani V H, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New Engl J Med, 2019, 380(18): 1695-1705.
22.	Popma J J, Deeb G M, Yakubov S J, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. New Engl J Med, 2019, 380(18): 1706-1715.
23.	Stone G W, Sabik J F, Serruys P W, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. New Engl J Med, 2016, 375(23): 2223-2235.
24.	Johnson K C, Whelton P K, Cushman W C, et al. Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 2018, 71(5): 848-857.
25.	Götberg M, Christiansen E H, Gudmundsdottir I J, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. New Engl J Med, 2017, 376(19): 1813-1823.
26.	Förstermann U, Xia Ning, Li Huige. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res, 2017, 120(4): 713-735.
27.	Ming M S, Rajendra K, Thirumala-Devi K. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev, 2017, 277(1): 61-75.
28.	Jin S C, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2, 871 congenital heart disease probands. Nat Genet, 2017, 49(11): 1593.
29.	章志伟, 王梦雪, 杨家鹏, 等. 越野行走对心血管疾病预后影响的meta分析. 中国循证医学杂志, 2019, 19(2): 147-155.
30.	Lear S A, Hu W, Rangarajan S, et al. The effect of physical activity on mortality and cardiovascular disease in 130000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet, 2017, 390(10113): 2643-2654.
31.	Roth G A, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol, 2017, 70(1): 1-25.
32.	Dong Z, Jing L, Miao W, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol, 2019, 16(4): 203-212.
33.	许津, 秦艳莉, 王凯, 等. 老年心血管危险因素与动脉硬化的相关性研究: 北上海社区老年人心血管病研究. 中国循证医学杂志, 2016, 16(12): 1365-1369.
34.	施仲伟. 阿司匹林在心血管疾病预防中的应用现状. 中华消化杂志, 2020, 40(5): 292-295.
35.	李婷婷, 聂志超, 田甜, 等. 阿司匹林用于心血管疾病一级预防的Meta分析. 中国循证医学杂志, 2019, 19(10): 1187-1194.
36.	Rothwell P M, Cook N R, Gaziano J M, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet, 2018, 392(10145): 387-399.
37.	McNeil J J, Wolfe R, Woods R L, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. New Engl J Med, 2018, 379(16): 1509-1518.
38.	McNeil J J, Nelson M R, Woods R L, et al. Effect of aspirin on all-cause mortality in the healthy elderly. New Engl J Med, 2018, 379(16): 1519-1528.
39.	Gaziano J M, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, 2018, 392(10152): 1036-1046.
40.	Claiborne J S, Donald E J, Mary F, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New Engl J Med, 2018, 379(3): 215-225.
41.	陈怡琳, 施仲伟. 抗凝新药利伐沙班临床研究进展. 心血管病学进展, 2009, 30(5): 810-813.
42.	Vittorio P, Gentian D, Giacomo Z, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132(13): 1365-1371.
43.	Young A M, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol, 2018, 36(20): 2017-2023.
44.	杨艳敏. COMPASS研究结果: 利伐沙班联合阿司匹林成为冠心病抗栓治疗新选择. 中华心律失常学杂志, 2017, 21(5): 459-460.
45.	于明坤, 明扬, 夏如玉, 等. 国际目标值法临床研究的文献和方法学特征分析. 中国循证医学杂志, 2019, 19(11): 1308-1316.
46.	晋军. 经导管主动脉瓣置换术的临床研究和应用进展. 第三军医大学学报, 2019, 41(19): 1873-1880.
47.	周浩. NR4A1调控的线粒体分裂和线粒体自噬在心肌微循环再灌注损伤中的机制研究. 北京: 中国人民解放军医学院, 2018.
48.	Zhou H, Zhu P, Guo J, et al. Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury. Redox Biol, 2017, 13: 498-507.
49.	刘栋. 线粒体分裂在大鼠心肌微血管内皮细胞缺血再灌注损伤中的作用及机制. 西安: 第四军医大学, 2013.
50.	Hao Z, Pingjun Z, Jin W, et al. Pathogenesis of cardiac ischemia reperfusion injury is associated with CK2α-disturbed mitochondrial homeostasis via suppression of FUNDC1-related mitophagy. Cell Death Differ, 2018, 25(6): 1080-1093.
51.	Hao Z, Chen S, Shunying H, et al. BI1 is associated with microvascular protection in cardiac ischemia reperfusion injury via repressing Syk-Nox2-Drp1-mitochondrial fission pathways. Angiogenesis, 2018, 21(3): 599-615.
52.	Xu A, Liu J, Liu P, et al. Mitochondrial translocation of Nur77 induced by ROS contributed to cardiomyocyte apoptosis in metabolic syndrome. Biochem Biophys Res Commun, 2014, 446(4): 1184-1189.
53.	Yue Z, Dennis B. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol, 2010, 30(8): 1535-1541.
54.	Zhou Hao, Wang Jin, Zhu Pingjun, et al. NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mitochondrial fission by CK2α. Basic Res Cardiol, 2018, 113(4): 23.
55.	Kyeongdae K, Dahee S, Seong L J, et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res, 2018, 123(10): 1127-1142.
56.	Carlos S, Quinte B, Kanin W, et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature, 2019, 569(7755): 236-240.
57.	Jaiswal S, Natarajan P, Silver A J, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. New Engl J Med, 2017, 377(2): 111-121.
58.	Fuster J J, MacLauchlan S, Zuriaga M A, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science, 2017, 355(6327): 842-847.

1. 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要. 中国循环杂志, 2019, 34(3): 209-220.
2. 科睿唯安. InCites - Cardiac&cardiovascular systems [EB/OL]. [2020/7/30]. http://incites.clarivate.com/#/explore/0/subject.
3. GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar M H, Reitsma M B, et al. Health effects of overweight and obesity in 195 countries over 25 years. New Engl J Med, 2017, 377(1): 13-27.
4. Lavie C J, Arena R, Alpert M A, et al. Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol, 2018, 15(1): 45-56.
5. Bohula E A, Wiviott S D, McGuire D K, et al. Cardiovascular safety of lorcaserin in overweigh or obese patients. New Engl J Med, 2018, 379(12): 1107-1117.
6. Aidin R, Araz R, Stefan F, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. New Engl J Med, 2017, 376(15): 1407-1418.
7. Holman R R, Bethel M A, Mentz R J, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New Engl J Med, 2017, 377(13): 1228-1239.
8. Neal B, Perkovic V, Mahaffey K W, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med, 2017, 377(7): 644-657.
9. Khera A V, Emdin C A, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and risk of coronary artery disease. New Engl J Med, 2016, 375(24): 2349-2358.
10. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet, 2017, 389(10064): 37-55.
11. Sabatine M S, Giugliano R P, Keech A C, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med, 2017, 376(18): 1713-1722.
12. Nicholls S J, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients the GLAGOV randomized clinical trial. J Am Med Assoc, 2016, 316(22): 2373-2384.
13. Bonaca M P, Nault P, Giugliano R P, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation, 2018, 137(4): 338-350.
14. Ridker P M, Everett B M, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New Engl J Med, 2017, 377(12): 1119-1131.
15. Ridker P M, MacFadyen J G, Thuren T, et al. Effect of interleukin-1 beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 2017, 390(10105): 1833-1842.
16. Ridker P M, MacFadyen J G, Everett B M, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, 2018, 391(10118): 319-328.
17. Eikelboom J W, Connolly S J, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. New Engl J Med, 2017, 377(14): 1319-1330.
18. Weitz J I, Lensing A W A, Prins M H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New Engl J Med, 2017, 5(5): 1211-1222.
19. Anand S S, Bosch J, Eikelboom J W, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, 2018, 391(10117): 219-229.
20. Reardon M J, Van Mieghem N M, Popma J J, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. New Engl J Med, 2017, 376(14): 1321-1331.
21. Mack M J, Leon M B, Thourani V H, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New Engl J Med, 2019, 380(18): 1695-1705.
22. Popma J J, Deeb G M, Yakubov S J, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. New Engl J Med, 2019, 380(18): 1706-1715.
23. Stone G W, Sabik J F, Serruys P W, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. New Engl J Med, 2016, 375(23): 2223-2235.
24. Johnson K C, Whelton P K, Cushman W C, et al. Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 2018, 71(5): 848-857.
25. Götberg M, Christiansen E H, Gudmundsdottir I J, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. New Engl J Med, 2017, 376(19): 1813-1823.
26. Förstermann U, Xia Ning, Li Huige. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res, 2017, 120(4): 713-735.
27. Ming M S, Rajendra K, Thirumala-Devi K. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev, 2017, 277(1): 61-75.
28. Jin S C, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2, 871 congenital heart disease probands. Nat Genet, 2017, 49(11): 1593.
29. 章志伟, 王梦雪, 杨家鹏, 等. 越野行走对心血管疾病预后影响的meta分析. 中国循证医学杂志, 2019, 19(2): 147-155.
30. Lear S A, Hu W, Rangarajan S, et al. The effect of physical activity on mortality and cardiovascular disease in 130000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet, 2017, 390(10113): 2643-2654.
31. Roth G A, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol, 2017, 70(1): 1-25.
32. Dong Z, Jing L, Miao W, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol, 2019, 16(4): 203-212.
33. 许津, 秦艳莉, 王凯, 等. 老年心血管危险因素与动脉硬化的相关性研究: 北上海社区老年人心血管病研究. 中国循证医学杂志, 2016, 16(12): 1365-1369.
34. 施仲伟. 阿司匹林在心血管疾病预防中的应用现状. 中华消化杂志, 2020, 40(5): 292-295.
35. 李婷婷, 聂志超, 田甜, 等. 阿司匹林用于心血管疾病一级预防的Meta分析. 中国循证医学杂志, 2019, 19(10): 1187-1194.
36. Rothwell P M, Cook N R, Gaziano J M, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet, 2018, 392(10145): 387-399.
37. McNeil J J, Wolfe R, Woods R L, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. New Engl J Med, 2018, 379(16): 1509-1518.
38. McNeil J J, Nelson M R, Woods R L, et al. Effect of aspirin on all-cause mortality in the healthy elderly. New Engl J Med, 2018, 379(16): 1519-1528.
39. Gaziano J M, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, 2018, 392(10152): 1036-1046.
40. Claiborne J S, Donald E J, Mary F, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New Engl J Med, 2018, 379(3): 215-225.
41. 陈怡琳, 施仲伟. 抗凝新药利伐沙班临床研究进展. 心血管病学进展, 2009, 30(5): 810-813.
42. Vittorio P, Gentian D, Giacomo Z, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132(13): 1365-1371.
43. Young A M, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol, 2018, 36(20): 2017-2023.
44. 杨艳敏. COMPASS研究结果: 利伐沙班联合阿司匹林成为冠心病抗栓治疗新选择. 中华心律失常学杂志, 2017, 21(5): 459-460.
45. 于明坤, 明扬, 夏如玉, 等. 国际目标值法临床研究的文献和方法学特征分析. 中国循证医学杂志, 2019, 19(11): 1308-1316.
46. 晋军. 经导管主动脉瓣置换术的临床研究和应用进展. 第三军医大学学报, 2019, 41(19): 1873-1880.
47. 周浩. NR4A1调控的线粒体分裂和线粒体自噬在心肌微循环再灌注损伤中的机制研究. 北京: 中国人民解放军医学院, 2018.
48. Zhou H, Zhu P, Guo J, et al. Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury. Redox Biol, 2017, 13: 498-507.
49. 刘栋. 线粒体分裂在大鼠心肌微血管内皮细胞缺血再灌注损伤中的作用及机制. 西安: 第四军医大学, 2013.
50. Hao Z, Pingjun Z, Jin W, et al. Pathogenesis of cardiac ischemia reperfusion injury is associated with CK2α-disturbed mitochondrial homeostasis via suppression of FUNDC1-related mitophagy. Cell Death Differ, 2018, 25(6): 1080-1093.
51. Hao Z, Chen S, Shunying H, et al. BI1 is associated with microvascular protection in cardiac ischemia reperfusion injury via repressing Syk-Nox2-Drp1-mitochondrial fission pathways. Angiogenesis, 2018, 21(3): 599-615.
52. Xu A, Liu J, Liu P, et al. Mitochondrial translocation of Nur77 induced by ROS contributed to cardiomyocyte apoptosis in metabolic syndrome. Biochem Biophys Res Commun, 2014, 446(4): 1184-1189.
53. Yue Z, Dennis B. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol, 2010, 30(8): 1535-1541.
54. Zhou Hao, Wang Jin, Zhu Pingjun, et al. NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mitochondrial fission by CK2α. Basic Res Cardiol, 2018, 113(4): 23.
55. Kyeongdae K, Dahee S, Seong L J, et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res, 2018, 123(10): 1127-1142.
56. Carlos S, Quinte B, Kanin W, et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature, 2019, 569(7755): 236-240.
57. Jaiswal S, Natarajan P, Silver A J, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. New Engl J Med, 2017, 377(2): 111-121.
58. Fuster J J, MacLauchlan S, Zuriaga M A, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science, 2017, 355(6327): 842-847.

Next Article
Comparative research on brain networks of children with attention deficit hyperactivity disorder and normal children based on visual cognitive tasks

Journal of Biomedical Engineering

Global research hot points on cardiovascular disease--bibliometric analysis based on the ESI hot papers

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content